NASDAQ
20.03.26 | 20:59
6,200 US-Dollar
+2,14 % +0,130
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SHATTUCK LABS Aktie jetzt für 0€ handeln | |||||
| 06.03. | Why Shattuck Labs Stock Soared More Than 53% Higher This Week | 2 | The Motley Fool | ||
| 06.03. | Shattuck Labs stock maintained at Buy by TD Cowen on drug data | 1 | Investing.com | ||
| 05.03. | Insights into Shattuck Labs Q4 Earnings | 1 | Benzinga.com | ||
| 05.03. | Shattuck Labs, Inc Q4 Loss Drops | 2 | RTTNews | ||
| 05.03. | Shattuck Labs, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 05.03. | Shattuck Labs GAAP EPS of -$0.12 beats by $0.01 | 1 | Seeking Alpha | ||
| 05.03. | Shattuck Labs, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 05.03. | Shattuck Labs, Inc.: Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights | 407 | GlobeNewswire (Europe) | Phase 1 clinical trial of SL-325 ongoing, with data expected in the second quarter of 2026 -Phase 2 clinical trial of SL-325 in patients with Crohn's disease expected to initiate in the third quarter... ► Artikel lesen | |
| 05.02. | Shattuck Labs, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 28.01. | Piper Sandler stuft Shattuck Labs mit "Overweight" ein und sieht massives Aufwärtspotenzial | 4 | Investing.com Deutsch | ||
| 28.01. | Piper Sandler initiates Shattuck Labs stock with Overweight rating | 1 | Investing.com | ||
| 22.01. | Shattuck Labs, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.01. | Why Shattuck Labs Stock Soared in December | 1 | The Motley Fool | ||
| 15.12.25 | Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 01.12.25 | Shattuck Labs stock rating upgraded to Buy by H.C. Wainwright | 2 | Investing.com | ||
| 07.11.25 | Shattuck Labs GAAP EPS of -$0.14 | 1 | Seeking Alpha | ||
| 06.11.25 | Shattuck Labs, Inc.: Shattuck Labs Reports Third Quarter 2025 Financial Results and Recent Business Highlights | 236 | GlobeNewswire (Europe) | -First participants dosed in Phase 1 clinical trial of SL-325 in healthy volunteers - - Closed a private placement of up to $103 million in August 2025 to support advancement of SL-325 - - Appointments... ► Artikel lesen | |
| 06.11.25 | Shattuck Labs, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.11.25 | Shattuck Labs, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.10.25 | Shattuck Labs stellt auf UEG-Kongress innovativen Ansatz zur IBD-Behandlung vor | 1 | Investing.com Deutsch |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NUREXONE BIOLOGIC | 0,428 | +4,65 % | NurExone zeigt Flagge: Technologie rückt auf internationale Bühne | ||
| ONCO-INNOVATIONS | 0,382 | +7,91 % | Onco-Innovations Limited: Onco-Innovations Announces Closing of Private Placement | Not for distribution to United States wire services or for dissemination in the United States VANCOUVER, BC / ACCESS Newswire / March 12, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H... ► Artikel lesen | |
| FRACTYL HEALTH | 0,432 | -1,03 % | FRACTYL HEALTH, INC. - 8-K, Current Report | ||
| ERASCA | 14,600 | -4,32 % | Erasca (ERAS) Adds 13%; Soars 310% YTD | ||
| MONTE ROSA THERAPEUTICS | 15,630 | -2,68 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates | Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipated... ► Artikel lesen | |
| IMMUNOVANT | 22,980 | -2,69 % | Bernstein initiates Immunovant stock coverage with neutral rating | ||
| KYMERA THERAPEUTICS | 77,91 | -2,06 % | Kymera Therapeutics (KYMR) to Present Phase 1b BroADen Trial Data for KT-621 at AAD 2026 | ||
| NURIX THERAPEUTICS | 14,430 | -3,25 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update | First patients dosed in DAYBreak registrational program for bexobrutideg in relapsed/refractory CLLPresented Phase 1 results at ASH 2025 that support bexobrutideg's potential best-in-class profile... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 60,92 | -5,18 % | Inhibrx Biosciences, Inc.: Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results | SAN DIEGO, March 19, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth... ► Artikel lesen | |
| QIAGEN | 34,805 | -1,28 % | Qiagen unter Druck, Zalando auf Erholungskurs: DAX-Ausblick | Der DAX befindet sich weiter auf Talfahrt. In der abgelaufenen Woche büßte das größte deutsche Börsenbarometer rund 144 Punkte ein und schloss -0,61% niedriger mit 23.447 Punkten. Die höchsten Verluste... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 11,210 | +0,54 % | Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results | FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 8,170 | -0,85 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy (epinephrine nasal spray) Commercialization | neffy delivers $72.2 million of U.S. net product revenue in first full year Intranasal epinephrine platform advances with Phase 2b CSU data expected mid-2026 Strong balance sheet of $245.0 million... ► Artikel lesen | |
| SPYGLASS PHARMA | 26,000 | +1,13 % | SpyGlass Pharma, Inc.: SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System | 97% of patients who received the BIM-IOL System off all topical IOP-lowering therapy at 12-months100% of BIM-IOL System patients achieved 20/32 or better BCDVA and a mean BCDVA equivalent to 20/20... ► Artikel lesen | |
| IMMIX BIOPHARMA | 9,110 | -5,89 % | Artificial Intelligence Technology Solutions, Inc.: AITX's RAD Confirms Immix, AWS, and Circadian Risk Participation at ISC West 2026 | Detroit, Michigan--(Newsfile Corp. - February 12, 2026) - Artificial Intelligence Technology Solutions, Inc. (OTCID: AITX) (the "Company"), a global leader in AI-driven security and productivity... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 46,080 | +0,96 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution | - ARCALYST- (rilonacept) Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively -- ARCALYST 2026 net product revenue expected to be $900 - $920 million... ► Artikel lesen |
Das Unternehmen SHATTUCK LABS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +2,14 % bei einem Aktienkurs von 6,200 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHATTUCK LABS INC finden Sie auf Wallstreet Online.